Poolbeg Pharma PLC (POLB) - Net Assets
Based on the latest financial reports, Poolbeg Pharma PLC (POLB) has net assets worth GBX11.93 Million GBX as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX12.36 Million) and total liabilities (GBX429.00K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX11.93 Million |
| % of Total Assets | 96.53% |
| Annual Growth Rate | -25.66% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 7.5 |
Poolbeg Pharma PLC - Net Assets Trend (2021–2024)
This chart illustrates how Poolbeg Pharma PLC's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Poolbeg Pharma PLC (2021–2024)
The table below shows the annual net assets of Poolbeg Pharma PLC from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | GBX9.27 Million | -35.79% |
| 2023-12-31 | GBX14.44 Million | -21.18% |
| 2022-12-31 | GBX18.32 Million | -18.85% |
| 2021-12-31 | GBX22.58 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Poolbeg Pharma PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1440700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | GBX100.00K | 1.08% |
| Other Comprehensive Income | GBX2.82 Million | 30.37% |
| Other Components | GBX23.10 Million | 249.11% |
| Total Equity | GBX9.27 Million | 100.00% |
Poolbeg Pharma PLC Competitors by Market Cap
The table below lists competitors of Poolbeg Pharma PLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
IN8BIO INC. DL-0001
F:6JH
|
$408.64K |
|
New Destiny Mining Corp
V:NED
|
$408.81K |
|
Kavango Resources PLC
LSE:KAV
|
$409.03K |
|
INDICE FINANCEIRO
SA:IFNC
|
$411.02K |
|
5D Acquisition Corp.
V:FIVD-P
|
$407.19K |
|
VPC Specialty Lending Investments PLC
LSE:VSL
|
$407.14K |
|
James Cropper PLC
LSE:CRPR
|
$406.89K |
|
in Style Group PLC
LSE:ITS
|
$406.88K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Poolbeg Pharma PLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 14,442,000 to 9,273,000, a change of -5,169,000 (-35.8%).
- Net loss of 5,790,000 reduced equity.
- Other comprehensive income increased equity by 2,076,000.
- Other factors decreased equity by 1,455,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX-5.79 Million | -62.44% |
| Other Comprehensive Income | GBX2.08 Million | +22.39% |
| Other Changes | GBX-1.46 Million | -15.69% |
| Total Change | GBX- | -35.79% |
Book Value vs Market Value Analysis
This analysis compares Poolbeg Pharma PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 256.12x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 105.18x to 256.12x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | GBX0.05 | GBX4.75 | x |
| 2022-12-31 | GBX0.04 | GBX4.75 | x |
| 2023-12-31 | GBX0.03 | GBX4.75 | x |
| 2024-12-31 | GBX0.02 | GBX4.75 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Poolbeg Pharma PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -62.44%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.11x
- Recent ROE (-62.44%) is below the historical average (-31.39%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -10.35% | 0.00% | 0.00x | 1.02x | GBX-4.59 Million |
| 2022 | -25.57% | 0.00% | 0.00x | 1.05x | GBX-6.52 Million |
| 2023 | -27.22% | 0.00% | 0.00x | 1.07x | GBX-5.38 Million |
| 2024 | -62.44% | 0.00% | 0.00x | 1.11x | GBX-6.72 Million |
Industry Comparison
This section compares Poolbeg Pharma PLC's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $5,234,616
- Average return on equity (ROE) among peers: -209.34%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Poolbeg Pharma PLC (POLB) | GBX11.93 Million | -10.35% | 0.04x | $407.51K |
| 4BASEBIO UK SOCIETAS (4BB) | $26.38 Million | -46.75% | 0.70x | $951.45K |
| Aptamer Group PLC (APTA) | $105.00K | -1761.52% | 18.66x | $205.09K |
| Arecor Therapeutics PLC (AREC) | $670.33K | -166.97% | 2.08x | $303.20K |
| Avacta Group PLC (AVCT) | $1.03 Million | -28.82% | 0.34x | $3.99 Million |
| BSF Enterprise Plc (BSFA) | $3.19 Million | -52.42% | 0.10x | $27.33K |
| Bioventix (BVXP) | $2.37 Million | 0.00% | 0.08x | $1.13 Million |
| Cizzle Biotechnology Holdings PLC (CIZ) | $5.05 Million | -26.39% | 0.56x | $106.10K |
| Amur Minerals Corporation (CRTX) | $23.13 Million | -10.58% | 0.03x | $73.96K |
| Fusion Antibodies PLC (FAB) | $188.00K | 0.00% | 3.37x | $190.14K |
| Faron Pharmaceuticals Oy (FARN) | $-9.76 Million | 0.00% | 0.00x | $602.85K |
About Poolbeg Pharma PLC
Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, focused on acquiring, developing, and commercialising of medicines for unmet medical needs in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; … Read more